Company Legal Name
Latest Valuation
Founded Year
Headquarter
Strand Therapeutics develops next-generation mRNA therapies engineered with proprietary genetic circuits to enable precise targeting of cancer cells and controlled immune system activation. Founded in 2017 and headquartered in Boston, the company differentiates itself through programmable mRNA technology that can sense cellular environments and respond accordingly, potentially addressing safety and efficacy limitations of current mRNA therapeutics. Strand's platform technology allows for conditional expression of therapeutic proteins only in target tissues, reducing systemic toxicity while maximizing therapeutic impact. The company continues advancing its pipeline of programmable mRNA candidates for oncology and immunology applications through preclinical and clinical development stages.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.





